The solubility test points, not upper limits, are as follows:
- DMF: 5 mg/ml
- DMSO: 5 mg/ml
- PBS (pH 7.2) (1:6): 0.1 mg/ml
- Ethanol: 3 mg/ml
SML2480
Mirabegron
≥98% (HPLC)
Synonym(s):
2-(2-Amino-1,3-thiazol-4-yl)-N-[4-[2-[((2R)-2-hydroxy-2-phenylethyl)amino]ethyl]phenyl]acetamide, 2-Amino-N-[4-[2-[[(2R)-2-hydroxy-2-phenylethyl]amino]ethyl]phenyl]-4-thiazoleacetamide, YM 178, YM178(R)-Mirabegron
Sign Into View Organizational & Contract Pricing
Select a Size
5 MG
791,00 kr.
25 MG
3.210,00 kr.
All Photos(1)
Select a Size
Change View
5 MG
791,00 kr.
25 MG
3.210,00 kr.
About This Item
Empirical Formula (Hill Notation):
C21H24N4O2S
CAS Number:
Molecular Weight:
396.51
MDL number:
UNSPSC Code:
12352200
NACRES:
NA.77
Recommended Products
Assay
≥98% (HPLC)
form
powder
optical activity
[α]/D -16 to -22°, c = 0.5 in methanol
color
white to beige
solubility
DMSO: 2 mg/mL, clear
storage temp.
2-8°C
SMILES string
O[C@@H](CNCCC1=CC=C(NC(CC2=CSC(N)=N2)=O)C=C1)C3=CC=CC=C3
InChI
1S/C21H24N4O2S/c22-21-25-18(14-28-21)12-20(27)24-17-8-6-15(7-9-17)10-11-23-13-19(26)16-4-2-1-3-5-16/h1-9,14,19,23,26H,10-13H2,(H2,22,25)(H,24,27)/t19-/m0/s1
InChI key
PBAPPPCECJKMCM-IBGZPJMESA-N
Looking for similar products? Visit Product Comparison Guide
Application
Mirabegron has been used as a β3-adrenergic receptor (β3-AR) agonist in an in vitro experiment to determine whether β3-AR stimulation specifically activates brown adipose tissue (BAT) thermogenesis in humans.
Biochem/physiol Actions
Mirabegron is a non-antimuscarinic orally active drug with the potential to treat patients with overactive bladder (OAB) symptoms. It aids in bladder relaxation by acting on neural control of the storage phase of micturition by targeting β3-AR. Mirabegron is also used to treat neurogenic detrusor overactivity (NDO) in pediatric patients.
Mirabegron is a potent and selective β3-adrenoceptor agonist that activates the β3 adrenergic receptor in the detrusor muscle in the bladder leading to muscle relaxation and an increase in bladder capacity.
potent and selective β3-adrenoceptor agonist
Signal Word
Warning
Hazard Statements
Precautionary Statements
Hazard Classifications
Repr. 2
Storage Class Code
11 - Combustible Solids
WGK
WGK 3
Flash Point(F)
Not applicable
Flash Point(C)
Not applicable
Choose from one of the most recent versions:
Certificates of Analysis (COA)
Lot/Batch Number
Don't see the Right Version?
If you require a particular version, you can look up a specific certificate by the Lot or Batch number.
Already Own This Product?
Find documentation for the products that you have recently purchased in the Document Library.
Customers Also Viewed
Rebecca Bragg et al.
The Consultant pharmacist : the journal of the American Society of Consultant Pharmacists, 29(12), 823-837 (2014-12-19)
To review the literature regarding the efficacy and safety of mirabegron for the treatment of overactive bladder (OAB). A literature search was performed using MEDLINE (PubMed) prior to December 31, 2013, using the terms "mirabegron" and "randomized-controlled trial." All published
Toshiyuki Takasu et al.
The Journal of pharmacology and experimental therapeutics, 321(2), 642-647 (2007-02-13)
We evaluated the pharmacological characteristics of (R)-2-(2-aminothiazol-4-yl)-4'-{2-[(2-hydroxy-2-phenylethyl)amino]-ethyl} acetanilide (YM178). YM178 increased cyclic AMP accumulation in Chinese hamster ovary (CHO) cells expressing human beta3-adrenoceptor (AR). The half-maximal effective concentration (EC50) value was 22.4 nM. EC50 values of YM178 for human beta1-
Pradeep Tyagi et al.
Expert opinion on drug safety, 10(2), 287-294 (2010-12-15)
Mirabegron is being developed as a new treatment for the management of overactive bladder (OAB). It is an orally active drug that works by activating the β(3)-adrenoceptor with a better safety profile than antimuscarinic drugs. However, long-term adverse effects are
Kentaro Konishi et al.
European journal of drug metabolism and pharmacokinetics, 43(3), 301-309 (2017-11-23)
Mirabegron is cleared by multiple mechanisms, including drug-metabolizing enzymes. One of the most important clearance pathways is direct glucuronidation. In humans, M11 (O-glucuronide), M13 (carbamoyl-glucuronide), and M14 (N-glucuronide) have been identified, of which M11 is one of the major metabolites
Susan J Keam
Paediatric drugs, 23(4), 411-415 (2021-06-01)
Mirabegron (MYRBETRIQ®), a beta-3 adrenergic agonist developed by Astellas Pharma Inc., is well established as a treatment for overactive bladder in adults and is available as extended-release (ER) tablets administered once daily. More recently, mirabegron has been investigated in pediatric
-
What is the solubility of item SML2480, Mirabegron?
1 answer-
Helpful?
-
Active Filters
Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.
Contact Technical Service
